Menü
Das neue sharewise ist da Übersichtlicher, schneller, mit heller und dunkler Ansicht — und allem, was du kennst. Jetzt ausprobieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Stock Buy: AT&T vs. C3.ai


AT (NYSE: T) and C3.ai (NYSE: AI) generally appeal to different types of tech investors. AT, one of the largest telecom companies in America, is usually owned for stability and dividends instead of aggressive gains. C3.ai, an enterprise AI software company that went public less than three years ago, is a speculative growth play.

Yet both of these stocks disappointed those target investors. If you had invested $1,000 in AT on April 11, 2022 -- the first day it traded separately from Warner Bros. Discovery -- your investment would only be worth about $760 today. If you had invested $1,000 in C3.ai's IPO on Dec 9, 2020, your investment would be worth less than $600. Let's see why these two stocks flopped, and if either one is still worth buying in this challenging market.

Image source: Getty Images.

Continue reading


Source Fool.com

Allergy Therapeutics PLC Aktie

0,053 €
-0,94 %
Die Allergy Therapeutics PLC Aktie verzeichnet heute einen leichten Verlust von -0,94 %.

Like: 0
T
Teilen

Kommentare